Back to Search Start Over

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Authors :
Pablo J. Camino
Fernando M. Ross
Sebastian Antelo
Pablo Rucci
Eulalia Rodriguez
Alejandra Matteaccio
N. Savoy
Waldo H. Belloso
Lucia Perez
Gabriela Vidiella
Maria Valeria Beruto
Leandro Burgos Pratx
Dean Follmann
Nora Fuentes
Gerardo A. Speroni
Ventura A Simonovich
Wanda Cornistein
Gabriel Funtowicz
Karina Rainero
Erica A. Miyazaki
Marcelo Vallone
Mariano Esperatti
Diego Mario Santoro
Diego Giunta
H. Clifford Lane
Diego Sebastian Ojeda
Omar A. Trabadelo
Walter E. Scordo
Marisa Sanchez
Pablo E. Pardo
Paula Scibona
Inés Ferniot
Hernán G. Michelangelo
Carolina Vázquez
Marcelo H. Losso
Julieta Pasquali
Esteban C. Nannini
Mariano Spotti
Andrea V. Gamarnik
Source :
The New England Journal of Medicine, New England Journal of Medicine, CONICET Digital (CONICET), Consejo Nacional de Investigaciones Científicas y Técnicas, instacron:CONICET
Publication Year :
2020
Publisher :
Massachusetts Medical Society, 2020.

Abstract

BACKGROUND:Convalescent plasma is frequently administered to patients with Covid-19 and hasbeen reported, largely on the basis of observational data, to improve clinical outcomes.Minimal data are available from adequately powered randomized, controlled trials. METHODS:We randomly assigned hospitalized adult patients with severe Covid-19 pneumoniain a 2:1 ratio to receive convalescent plasma or placebo. The primary outcome wasthe patient?s clinical status 30 days after the intervention, as measured on a six-pointordinal scale ranging from total recovery to death. RESULTS:A total of 228 patients were assigned to receive convalescent plasma and 105 toreceive placebo. The median time from the onset of symptoms to enrollment inthe trial was 8 days (interquartile range, 5 to 10), and hypoxemia was the mostfrequent severity criterion for enrollment. The infused convalescent plasma had amedian titer of 1:3200 of total SARS-CoV-2 antibodies (interquartile range, 1:800 to1:3200]. No patients were lost to follow-up. At day 30 day, no significant differencewas noted between the convalescent plasma group and the placebo group in thedistribution of clinical outcomes according to the ordinal scale (odds ratio, 0.83(95% confidence interval [CI], 0.52 to 1.35; P=0.46). Overall mortality was 10.96%in the convalescent plasma group and 11.43% in the placebo group, for a risk difference of −0.46 percentage points (95% CI, −7.8 to 6.8). Total SARS-CoV-2 antibodytiters tended to be higher in the convalescent plasma group at day 2 after the intervention. Adverse events and serious adverse events were similar in the two groups. CONCLUSIONS:no significant differences were observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo.(PlasmAr ClinicalTrials.gov number, NCT04383535.) Fil: Simonovich, Ventura A.. Hospital Italiano. Departamento de Medicina. Servicio de Clinica Medica.; Argentina Fil: Burgos Pratx, Leandro D.. Hospital Italiano. Departamento de Medicina. Servicio de Clinica Medica.; Argentina Fil: Scibona, Paula. Hospital Italiano. Departamento de Medicina. Servicio de Clinica Medica.; Argentina Fil: Beruto, Maria Valeria. No especifíca; Fil: Vallone, Miguel Gabriel. No especifíca; Fil: Vázquez, C.. No especifíca; Fil: Savoy, N.. No especifíca; Fil: Giunta, Diego Hernan. No especifíca; Fil: Pérez, L.G.. No especifíca; Fil: Sánchez, M.L.. No especifíca; Fil: Gamarnik, Andrea Vanesa. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina Fil: Ojeda, D.S.. No especifíca; Fil: Santoro, D.M.. No especifíca; Fil: Camino, P. J.. No especifíca; Fil: Antelo, S.. No especifíca; Fil: Rainero, K.. No especifíca; Fil: Vidiella, G. P.. No especifíca; Fil: Miyazaki, E. A.. No especifíca; Fil: Cornistein, W.. No especifíca; Fil: Trabadelo, O. A.. No especifíca; Fil: Ross, F. M.. No especifíca; Fil: Spotti, M.. No especifíca; Fil: Funtowicz, G.. No especifíca; Fil: Scordo, W. E.. No especifíca; Fil: Losso, M. H.. No especifíca; Fil: Ferniot, I.. No especifíca; Fil: Pardo, P. E.. No especifíca; Fil: Rodriguez, E.. No especifíca; Fil: Rucci, P.. No especifíca; Fil: Pasquali, J.. No especifíca; Fil: Fuentes, N. A.. No especifíca; Fil: Esperatti, M.. No especifíca; Fil: Speroni, G. A.. No especifíca; Fil: Nannini, Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; Argentina Fil: Matteaccio, A.. No especifíca; Fil: Michelangelo, H.G.. No especifíca; Fil: Follmann, D.. No especifíca; Fil: Lane, H. Clifford. No especifíca; Fil: Belloso, Waldo Horacio. Hospital Italiano. Departamento de Medicina. Servicio de Clinica Medica.; Argentina

Details

Language :
English
Database :
OpenAIRE
Journal :
The New England Journal of Medicine, New England Journal of Medicine, CONICET Digital (CONICET), Consejo Nacional de Investigaciones Científicas y Técnicas, instacron:CONICET
Accession number :
edsair.doi.dedup.....14268c97335944b912b0ebd47cd0dd3d
Full Text :
https://doi.org/10.1056/NEJMoa2031304